Reuters logo
BRIEF-SillaJen and Transgene enroll first European patient in Phase 3 trial for Pexa-Vec
April 24, 2017 / 5:00 PM / 7 months ago

BRIEF-SillaJen and Transgene enroll first European patient in Phase 3 trial for Pexa-Vec

April 24 (Reuters) - SillaJen Inc:

* SillaJen and Transgene announce the enrollment of the first European patient in multinational Phase 3 trial for Pexa-Vec in advanced liver cancer

* Enrollment of the first European patient triggers a $4 million USD milestone to be paid to Sillajen by Transgene Source text for Eikon: Further company coverage:, (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below